The phase 3 ORCA-3 trial confirms 12 weeks of therapy with the partial nicotine receptor agonist cytisinicline (awaiting FDA approval) significantly enhances sustained smoking cessation rates through 6 months (20.5%) versus placebo (4%) and without the nausea and nightmares seen with alternative pharmacologics already on the market. | Rigotti, JAMA Intern Med 2025
